副研究员
陈志翱 副研究员
副研究员,博士
E-mail: chenzhiao@shca.org.cn
 

  2004年毕业于复旦大学上海医学院临床专业,获医学学士学位。2009年毕业于复旦大学上海医学院医学分子病毒学重点实验室,获医学博士学位。2009年-2013年在上海市肿瘤研究所癌基因及相关基因国家重点实验室工作,2013年至今在复旦大学附属肿瘤医院肿瘤研究所工作,主要从事消化道肿瘤基因功能组学、转录重编程及与表观遗传学修饰互作的研究。近5年主持项目包括高校博士点专项科研基金项目一项,上海市自然科学基金青年基金一项,上海市自然科学基金面上项目一项,国家自然科学基金一项,并作为课题骨干参与国家科技重大专项两项及国家自然科学基金多项。近5年主要研究成果发表于Cell Death & Disease, Frontiers in Pharmacology, Carcinogenesis, Cancer Science, Gastroenterology, Hepatology,Oncogene以及Journal of Immunology等杂志。在学术任职方面,担任《肿瘤》、Cancel Cell International、Oncology Reports、Oncotarget和Biomedicine & Pharmacotherapy等国内外肿瘤学期刊审稿专家。


研究领域:

  消化系统恶性肿瘤发生与转移的分子机制和临床转化,主要包括:
  1.肿瘤相关基因功能及细胞信号转导研究;
  2.肿瘤表观遗传学修饰及转录重编程的研究。


代表性论著:

  1. Zhiao Chen#, Xinyuan Lu#, Deshui Jia, Ying Jing, Di Chen, Qifeng Wang, Fangyu Zhao, Jinjun Li, Ming Yao, Wenming Cong, Xianghuo He*. Hepatic SMARCA4 Predicts HCC Recurrence and Promotes Tumour Cell Proliferation by Regulating SMAD6 Expression. Cell Death & Disease, 2018 Jan 19; 9(2):59.
  2. Xin-Yuan Lu#, Di Chen#, Xiao-Yuan Gu#, Jie Ding, Ying-Jun Zhao, Qian Zhao, Ming Yao, Zhi-Ao Chen*, Xiang-Huo He* and Wen-Ming Cong*. Predicting value of ALCAM as a target gene of microRNA-483-5p in patients with early recurrence in hepatocellular carcinoma. Frontiers in Pharmacology, 2018 Jan 12; 8:973.
  3. Tangjian Li#, Shengli Li#, Di Chen, Bing Chen, Tao Yu, Fangyu Zhao, Qifeng Wang, Ming Yao, Shenglin Huang, Zhiao Chen*Xianghuo He*. Transcriptomic analyses of RNA-binding proteins reveal eIF3c promotes cell  proliferation in hepatocellular carcinoma. Cancer Sci, 2017 May; 108(5):877-885.
  4. Zhaoping Qiu#, Weijie Guo#, Qifeng Wang, Zhiao Chen, Shenglin Huang, Fangyu Zhao, Ming Yao, Yingjun Zhao*, Xianghuo He*. MicroRNA-124 Reduces Pentose Phosphate Pathway and Proliferation by Targeting PRPS1 and RPIA mRNAs in Human Colorectal Cancer Cells. Gastroenterology, 2015 Nov; 149(6):1587-1598.
  5. Yuping Huang#, Ning Tan, Deshui Jia, Ying Jing, Qifeng Wang, Zhe Li, Jiwei Zhang, Li Liu, Jinjun Li, Zhiao Chen*, Xianghuo He*. Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer. Tumor Biology, 2015; 36(12), 9753-9761.
  6. Weijie Guo#, Zhaoping Qiu#, Zhichao Wang, Qifeng Wang, Ning Tan, Taoyang Chen, Zhiao Chen, Shengling Huang, Jianren Gu, Jinjun Li, Ming Yao, Yingjun Zhao*, Xianghuo He*. MiR-199a-5p is negatively associated with the malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatology, 2015 Oct; 62(4):1132-44.
  7. Zhiao Chen#, Zhichao Wang#, Weijie Guo, Zhenfeng Zhang, Fangyu Zhao, Yingjun Zhao, Deshui Jia, Jie Ding, Hui Wang, Ming Yao and Xianghuo He*. TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma. Oncogene, 2015; 34(30): 3946-56.
  8. Zhiao Chen#Xinyuan Lu#, Zhichao Wang, Guangzhi Jin, Qifeng Wang, Di Chen, Taoyang Chen, Jinjun Li, Jia Fan, Wenming Cong, Qiang Gao, and  Xianghuo He*. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget, 2015; 6(4): 2539-48
  9. Sen Wang#Zhiao Chen#, Conghua Hu, Fangxin Qian, Yuming Cheng, Min Wu, Bisheng Shi, Jieliang Chen, Yunwen Hu and Zhenghong Yuan*. Hepatitis B virus 1 surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. The Journal of Immunology, 2013; 190(10):5142-51.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有